Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.

Authors :: Conteduca V
Caffo O
Fratino L
Lo Re G
Basso U
D'Angelo A
Donini M
Verderame F
Ratta R
Procopio G
Campadelli E
Massari F
Gasparro D
Ermacora P
Messina C
Giordano M
Alesini D
Zagonel V
Veccia A
Lolli C
Maines F
De Giorgi U
Source :: Future oncology (London, England) [Future Oncol] 2015; Vol. 11 (21), pp. 2881-91. Date of Electronic Publication: 2015 Oct 05.
Publication Year :: 2015
Abstract: Background: The objective of this study was to analyze the impact of visceral metastases in castration-resistant prostate cancer (CRPC) treated with abiraterone.<br />Materials & Methods: All CRPC patients received abiraterone 1000 mg daily plus prednisone 10 mg orally daily. Liver and lung metastases were considered as visceral metastases.<br />Results: Of 265 CRPC patients, 49 had visceral metastases. Results on progression-free survival were not significantly different in patients with or without visceral metastases. Conversely, the median overall survival between the two groups was 12.4 and 18.5 months (p = 0.01), respectively, and median overall survival of patients with liver-only disease versus other sites was 10.5 versus 18.5 months (p = 0.006), respectively.<br />Conclusion: Visceral disease appears to be an important predictor of clinical outcome in CRPC patients treated with abiraterone.

Full Text Access

Tools